| Ticker: GERN | 200 Constitution Drive | |
| Exchange: NASDAQ-National Market | Menlo Park, California 94025 | |
| Industry: Manufacturing | (415) 473-7700 |
| Type of Shares: | Common Shares | Filing Date: | 6/12/96 | |
| U.S. Shares: | 2,000,000 | Offer Date: | 7/30/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $11.00 - $13.00 | |
| Primary Shares: | 2,000,000 | Offer Price: | $8.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.56 | |
| Offering Amount: | $24,000,000 | Selling: | $0.34 | |
| Expenses: | $875,000 | Reallowance: | $0.10 | |
| Shares Out After: | 10,012,280 |
| Manager | Tier | Phone |
| J.P. Morgan Securities Inc. | Lead Manager | (212) 648-9922 |
| Montgomery Securities | Co-manager | 4156272220 |
| Salomon Brothers Inc. | Co-manager | (212) 783-2947 |
| Auditor: Ernst & Young | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $5.49 | $1.34 | $0.00 | Assets: | $18.10 |
| Net Income: | -$8.20 | -$2.44 | -$2.95 | Liabilities: | $3.44 |
| EPS: | -$1.20 | -$0.31 | Equity: | $14.66 | |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is a biopharmaceutical company exclusively focused on discovering and developing therapeutic and diagnostic products based upon common biological mechanisms underlying cancer and other age-related diseases. As the pioneer in researching these mechanisms, the company focuses on telomeres, which are structures at the ends of chromosomes that the company has shown act as a molecular "clock" of cellular aging, and telomerase, an enzyme which appears to stop the "clock" and lead to cellular immortality. The company and its collaborators have established that these mechanisms play a role in cancer and many other age-related diseases and conditions, and thus the company believes it has a broadly applicable, proprietary platform for discovering and developing novel small molecule therapeutics and diagnostics for such diseases. The most advanced of the company's three therapeutic programs is in the area of telomerase inhibition for the treatment of cancer. The company will continue to build upon its leadership position in the field of telomere biology and telomerase regulation by selectively collaborating with companies and research institutions and by aggressively pursuing an extensive patent portfolio. |
| Use of Proceeds |
| The proceeds from the offering will be used for research and development, acquisition of laboratory and other equipment, working capital and other general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.